Dynavax Technologies Corporation

Equities

DVAX

US2681582019

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-14 EDT			5-day change	1st Jan Change
11.55 ^USD	-3.83%		-4.23%	-17.38%

06-10	Transcript : Dynavax Technologies Corporation Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 04:00 PM
05-24	Dynavax Technologies Corporation Reappoints Ernst & Young LLP as Independent Registered Public Accounting Firm	CI

Dynavax Technologies Corporation Reappoints Ernst & Young LLP as Independent Registered Public Accounting Firm

May 24, 2024 at 04:05 pm

Dynavax Technologies Corporation at its annual meeting held on May 23, 2024, announced the reappointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.

Latest news about Dynavax Technologies Corporation

Transcript : Dynavax Technologies Corporation Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 04:00 PM	06-10
Dynavax Technologies Corporation Reappoints Ernst & Young LLP as Independent Registered Public Accounting Firm	05-24	CI
Dynavax Technologies Notified by US FDA That Application for Four-Dose Course of Hepatitis B Vaccine Lacks Sufficient Data	05-14	MT
Dynavax Application for Hepatitis B Treatment Ruled Insufficient by FDA	05-14	DJ
US FDA declines to approve expanded use of Dynavax's hepatitis B vaccine	05-14	RE
Dynavax Technologies Corporation Provides Regulatory Update on sBLA for Four-Dose HEPLISAV-B® Regimen for Adults on Hemodialysis in the U.S	05-14	CI
Transcript : Dynavax Technologies Corporation, Q1 2024 Earnings Call, May 08, 2024	05-08
Earnings Flash (DVAX) DYNAVAX TECHNOLOGIES Posts Q1 Revenue $50.8M, vs. Street Est of $55M	05-08	MT
Dynavax Technologies Corporation Reaffirms Financial Guidance for the Full Year 2024	05-08	CI
Dynavax Technologies Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08	CI
Dynavax Technologies Corporation Announces Chief Financial Officer Changes	04-01	CI
Dynavax Technologies Reports Breakeven Q4 Earnings, Lower Revenue	02-23	MT
Transcript : Dynavax Technologies Corporation, Q4 2023 Earnings Call, Feb 22, 2024	02-22
Dynavax Technologies Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	02-22	CI
Earnings Flash (DVAX) DYNAVAX TECHNOLOGIES Reports Q4 Revenue $55.6M, vs. Street Est of $52.7M	02-22	MT
Dynavax Technologies Corporation Provides Revenue Guidance for the Year 2024	02-22	CI
Dynavax Technologies Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-22	CI
Goldman Sachs Initiates Dynavax Technologies at Neutral Rating With $20 Price Target	02-01	MT
Transcript : Dynavax Technologies Corporation Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 11:15 AM	01-11
Dynavax Technologies Corporation(NasdaqGS:DVAX) added to NASDAQ Biotechnology Index	12-18	CI
Dynavax Technologies Insider Sold Shares Worth $300,000, According to a Recent SEC Filing	11-07	MT
Dynavax Technologies Insider Sold Shares Worth $282,400, According to a Recent SEC Filing	11-03	MT
Transcript : Dynavax Technologies Corporation, Q3 2023 Earnings Call, Nov 02, 2023	11-02
Earnings Flash (DVAX) DYNAVAX TECHNOLOGIES Reports Q3 Revenue $69.5M, vs. Street Est of $61.4M	11-02	MT
Dynavax Technologies Corporation Revises Earnings Guidance for the Full Year 2023	11-02	CI

Chart Dynavax Technologies Corporation

Duration

Period

More charts

Company Profile

Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company, which is engaged in developing and commercializing vaccines. The Company's products include HEPLISAV-B hepatitis B vaccine and CpG 1018. Its HEPLISAV-B ((Recombinant)(Adjuvanted) is indicated for the prevention of infection caused by all known subtypes of the hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose hepatitis B vaccine for adults. It also manufactures and sells CpG 1018 adjuvant, the adjuvant used in HEPLISAV-B. It is also engaged in developing a multi-program clinical pipeline leveraging CpG 1018 adjuvant to develop improved vaccines for indications with unmet medical needs. Its Pipeline programs include vaccine candidates under development for shingles, tetanus, diphtheria, and pertussis (Tdap) and plague. Its Shingles vaccine program Z-1018, which is an investigational vaccine candidate being developed for the prevention of shingles in adults aged 50 and older.

Sector

Biotechnology & Medical Research

Calendar

2024-07-31 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Dynavax Technologies Corporation

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

11.55 USD

Average target price

25.91 USD

Spread / Average Target

+124.35%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
DYNAVAX TECHNOLOGIES CORPORATION	-17.38%	1.51B
VERTEX PHARMACEUTICALS INCORPORATED	+18.15%	124B
REGENERON PHARMACEUTICALS, INC.	+18.02%	112B
ARGENX SE	+4.60%	22.94B
BEIGENE, LTD.	-9.86%	17.02B
GENMAB A/S	-16.26%	16.88B
WUXI APPTEC CO., LTD.	-39.94%	16.87B
NEUROCRINE BIOSCIENCES, INC.	+2.80%	13.63B
SAREPTA THERAPEUTICS, INC.	+27.39%	11.61B
INSMED INCORPORATED	+106.26%	10.31B

Bio Therapeutic Drugs